
Allarity Therapeutics (ALLR) Stock Forecast & Price Target
Allarity Therapeutics (ALLR) Analyst Ratings
Bulls say
Allarity Therapeutics is a clinical-stage biopharmaceutical company leveraging its proprietary DRP technology to develop precision medicine for patients with high unmet medical needs, and its lead drug Stenoparib is showing promise in clinical trials for advanced recurrent ovarian cancer. Although concerns about long development timelines and high risks remain, strong growth prospects and a reasonable valuation make Allarity Therapeutics an attractive investment opportunity. In its Q1 2026 fiscal results, the company reported minimal revenue but managed a smaller net loss than expected, indicating promising financial management.
Bears say
Allarity Therapeutics is facing significant risks, as its balance sheet and liquidity are at risk due to only having $15 million in cash and $1 million in debt. There is potential for failure in demonstrating the safety and efficacy of its product candidates, along with potential challenges in gaining and maintaining regulatory approvals and commercializing its product. Market competition and changing macroeconomic factors also pose potential challenges, leading to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Allarity Therapeutics (ALLR) Analyst Forecast & Price Prediction
Start investing in Allarity Therapeutics (ALLR)
Order type
Buy in
Order amount
Est. shares
0 shares